Brief: Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
25/03/2025 11:34
March 25 (Reuters) - Relmada Therapeutics Inc RLMD.O: RELMADA THERAPEUTICS LICENSES PHASE 2 BLADDER CANCER CANDIDATE, NDV-01, FROM TRIGONE PHARMA, LTD. RELMADA- UNDER DEAL,CO TO MAKE $3.5 MILLION UPFRONT PAYMENT AND ISSUE 3,017,420 SHARES OF COMMON STOCK RELMADA- TO PAY UP TO $200 MILLION IN DEVELOPMENT, REGULATORY,SALES MILESTONES PENDING SUCCESSFUL COMMERCIALIZATION Source text: ID:nGNXbsG70Y Further company coverage: RLMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million